检索结果-南通市图书馆

The Establishment and Validation of the Human U937 Cell Line as a Cellular Model to Screen immunomodulatory agents Regulating Cytokine Release Induced by Influenza Virus Infection

引用

Virologica Sinica 2019年第6期34卷 648-661页

作者： Ge Liu Si Chen Ao Hu Li Zhang Wenyu Sun Jungang Chen Wei Tang Haiwei Zhang Chunlan Liu Chang Ke Xulin Chen State Key Laboratory of Virology Wuhan Institute ofVirologyChinese Academy of SciencesWuhan 430071China University of Chinese Academy of Sciences Beijing 100049China Wuhan Virolead Biopharmaceutical Company Wuhan 430075China

Severe influenza infections are often associated with the excessive induction of pro-inflammatory cytokines,which is also referred to as"cytokine storms".Several studies have shown that cytokine storms are directly associated with influenzainduced fatal acute lung injury and acute respiratory distress *** to the narrow administration window,current antiviral therapies are often *** efforts to use immunomodulatory agents alone or in combination with antiviral agents in the treatment of influenza in animal models have resulted in the achievement of protective effects accompanied with reduced cytokine ***,there are no immunomodulatory drugs for influenza available for clinical *** models,despite being ideal to study the anti-inflammatory responses to influenza virus infection,are very costly and ***,there is an urgent need to establish fast and economical screening methods using cellbased models to screen and develop novel immunomodulatory *** this study,we screened seven human cell lines and found that the human monocytic cell U937 supports the replication of different subtypes of influenza viruses as well as the production of the important pro-inflammatory cytokines and was selected to develop the cell-based *** U937 cell model was validated by testing a panel of known antiviral and immunomodulatory agents and screening a drug library consisting of 1280 compounds comprised mostly of FDA-approved *** demonstrated that the U937 cell model is robust and suitable for the high-throughput screening of immunomodulators and antivirals against influenza infection.

关键词： Influenza immunomodulatory agent U937 cell CCL2 CXCL10

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab:A case report

引用

World Journal of Clinical Cases 2022年第34期10卷 12703-12710页

作者： Xian Li Xiao-Hong Pan Qiu Fang Yun Liang Department of Hematology The Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310009Zhejiang ProvinceChina Department of Cardiology The Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310009Zhejiang ProvinceChina Department of Hematology Huzhou Central HospitalAffiliated Huzhou HospitalZhejiang University School of MedicineHuzhou 313099Zhejiang ProvinceChina

BACKGROUND Immunoglobulin light chain(AL)amyloidosis is a rare disease characterized by deposition of ALs essentially in any organ or tissue,with cardiac involvement being very frequent(61%).Early diagnosis is of high importance because early initiation of treatment in AL amyloidosis may improve *** the administration of immunotherapeutic agents,in particular bortezomib and daratumumab,which have improved the outcomes of AL amyloidosis,antiplasma cell therapy remains suboptimal for some *** SUMMARY We report the case of a 55-year-old man presenting with heart failure who was diagnosed with cardiac AL amyloidosis by an endomyocardial *** experienced a short-term hematological remission with no organ response after being administered a bortezomib-daratumumab containing *** treatment was switched to pomolidomide due to pulmonary involvement and progressive pleural effusion,in which flow cytometry analysis showed abnormal plasma *** two cycles of this regimen,the pleural effusion was controlled effectively with no *** This case emphasizes the crucial role of endomyocardial biopsy in early diagnosis of cardiac amyloidosis and suggests that pomolidomide may be an effective treatment for patients with AL amyloidosis that is relapsed/refractory to both bortezomib and daratumumab.

关键词： Immunoglobulin light chain amyloidosis Relapsed/refractory Pleural effusion Endomyocardial biopsy immunomodulatory agent Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：